A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
The focus is no longer just AI-generated worlds, but how those worlds become structured digital products
Updated
February 20, 2026 6:50 PM
The inside of a pair of HTC VR goggles. PHOTO: UNSPLASH
As AI tools improve, creating 3D content is becoming faster and easier. However, building that content into interactive experiences still requires time, structure and technical work. That difference between generation and execution is where HTC VIVERSE and World Labs are focusing their new collaboration.
HTC VIVERSE is a 3D content platform developed by HTC. It provides creators with tools to build, refine and publish interactive virtual environments. Meanwhile, World Labs is an AI startup founded by researcher Fei-Fei Li and a team of machine learning specialists. The company recently introduced Marble, a tool that generates full 3D environments from simple text, image or video prompts.
While Marble can quickly create a digital world, that world on its own is not yet a finished experience. It still needs structure, navigation and interaction. This is where VIVERSE fits in. By combining Marble’s world generation with VIVERSE’s building tools, creators can move from an AI-generated scene to a usable, interactive product.
In practice, the workflow works in two steps. First, Marble produces the base 3D environment. Then, creators bring that environment into VIVERSE, where they add game mechanics, scenes and interactive elements. In this model, AI handles the early visual creation, while the human creator defines how users explore and interact with the world.
To demonstrate this process, the companies developed three example projects. Whiskerhill turns a Marble-generated world into a simple quest-based experience. Whiskerport connects multiple AI-generated scenes into a multi-level environment that users navigate through portals. Clockwork Conspiracy, built by VIVERSE, uses Marble’s generation system to create a more structured, multi-scene game. These projects are not just demos. They serve as proof that AI-generated worlds can evolve beyond static visuals and become interactive environments.
This matters because generative AI is often judged by how quickly it produces content. However, speed alone does not create usable products. Digital experiences still require sequencing, design decisions and user interaction. As a result, the real challenge is not generation, but integration — connecting AI output to tools that make it functional.
Seen in this context, the collaboration is less about a single product and more about workflow. VIVERSE provides a system that allows AI-generated environments to be edited and structured. World Labs provides the engine that creates those environments in the first place. Together, they are testing whether AI can fit directly into a full production pipeline rather than remain a standalone tool.
Ultimately, the collaboration reflects a broader change in creative technology. AI is no longer only producing isolated assets. It is beginning to plug into the larger process of building complete experiences. The key question is no longer how quickly a world can be generated, but how easily that world can be turned into something people can actually use and explore.